The global imfinzi market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Imfinzi is a human immunoglobulin G1 kappa monoclonal antibody that prevents programmed cell death ligand 1 from interacting with PD-1. Imfinzi is a checkpoint inhibitor medication. It is a prescription drug that is used to treat adults who […]